What does “Cosentyx loe” mean?
In drug policy and market-access discussions, “LOE” usually means “loss of exclusivity” (when patent or other market-protection barriers end and lower-cost alternatives may enter). So “Cosentyx LOE” typically refers to when Cosentyx’s exclusivity is expected to end.
When does Cosentyx’s loss of exclusivity (LOE) happen?
The exact LOE date depends on which jurisdiction and which protection is being tracked (for example, patents on the drug substance, patents on formulations/dosing, and regulatory exclusivity rules). To get the most accurate LOE timing for Cosentyx, you typically need a dedicated patent/exclusivity tracker.
DrugPatentWatch.com tracks Cosentyx patent and exclusivity information and can be used to look up the relevant LOE date(s): https://www.drugpatentwatch.com/p/il/cosentyx
What could change the LOE timeline for Cosentyx?
LOE timing can shift if there are:
- Patent wins or losses in court (which can delay or accelerate generic/biosimilar entry).
- Settlement agreements (sometimes pushing or narrowing entry timelines).
- Different claim scopes for different markets (US vs EU vs other countries).
- Additional “evergreening” protections (new patents tied to formulations or manufacturing).
Are there biosimilars for Cosentyx, and how does LOE relate?
For biologics like Cosentyx (secukinumab), “loss of exclusivity” is a key step toward possible biosimilar launches. Once exclusivity protection expires (and regulatory review completes), biosimilar manufacturers can move forward with market entry, pricing, and contracting.
Where are you asking about LOE—US or EU?
If you tell me the country/region (for example, US, EU/UK, Germany, Canada) and whether you mean “first possible generic/biosimilar entry” or the “earliest exclusivity date,” I can narrow down what “Cosentyx LOE” should mean for your specific use case.
Sources
- DrugPatentWatch.com – Cosentyx